Contracts › 75N93024C00008
75N93024C00008: To Develop a Novel Modulator Targeting Proteostasis for the Treatment of M. Tuberculosis.
Awarded to The Global Alliance for Tb Drug Development Inc by National Institutes of Health (NIH).
$2.5Mobligated
$9.9Mpotential value
28 February 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93024C00008 |
|---|---|
| Awardee | The Global Alliance for Tb Drug Development Inc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | NY |
| Offers received | 18 |
| Period of performance | 10 May 2024 to 28 February 2027 |
| Potential end | 30 April 2028 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record